Treatment of Campylobacter Infection

First-Line Treatment Options

• The Infectious Diseases Society of America recommends azithromycin as the first-line treatment for Campylobacter infections, with a clinical cure rate of 96% 1
• Early treatment with azithromycin (within 72 hours of symptom onset) is most effective in reducing symptom duration from 50-93 hours to 16-30 hours 1
• The American College of Physicians and the Infectious Diseases Society of America support azithromycin as the preferred treatment, especially in regions with high fluoroquinolone resistance 1

Alternative Treatment Options

• Erythromycin can be used as an alternative if azithromycin is unavailable, although it is less effective 1

Treatment Considerations Based on Disease Severity

Mild to Moderate Disease

• Most Campylobacter infections are self-limiting and resolve without specific antimicrobial treatment within 3-5 days 2
• Consider supportive care only for immunocompetent patients with mild symptoms 3

Severe Disease

• Antibiotic treatment is indicated for patients with bloody diarrhea 3
• Antibiotic treatment is indicated for patients with high fever 1
• Antibiotic treatment is indicated for patients with severe abdominal pain 3
• Antibiotic treatment is indicated for patients with prolonged symptoms (>1 week) 3
• Antibiotic treatment is indicated for immunocompromised patients 1

Special Populations

• Immunocompromised patients should always receive antibiotic treatment, even for mild infections, due to the risk of systemic spread 1
• HIV-infected persons are at higher risk for infection with non-jejuni non-coli Campylobacter species and may require specialized testing and treatment 4, 5

Antimicrobial Resistance Considerations

• Fluoroquinolone resistance among Campylobacter has increased dramatically worldwide, exceeding 90% in Southeast Asia 1
• Clinical failure occurs in approximately 33% of patients treated with fluoroquinolones when the isolate is resistant 1
• Macrolide (azithromycin, erythromycin) resistance remains relatively low at around 4% for travel-related infections 1
• Consider local resistance patterns when choosing empiric therapy 1

Supportive Care

• Initial rehydration is critical, particularly for patients with severe diarrhea or signs of dehydration 1
• Oral rehydration solutions are recommended for most patients 1
• Avoid antimotility agents as they may prolong bacterial shedding and worsen symptoms 2
• Continue age-appropriate feeding as tolerated 1

Monitoring and Follow-up

• If no improvement or worsening symptoms occur after 48 hours of treatment, reassess diagnosis and consider alternative antibiotics based on susceptibility testing 1
• No routine follow-up stool cultures are needed if symptoms resolve 1
• Diarrhea persisting beyond 10-14 days warrants further evaluation 2

Common Pitfalls and Caveats

• Using fluoroquinolones empirically without considering local resistance patterns can lead to treatment failure and prolonged illness 1
• Delaying treatment beyond 72 hours can reduce the effectiveness of azithromycin and other antibiotics 1
• Discontinuing antibiotics prematurely before completing the full course can lead to treatment failure 1
• Be aware of potential post-infectious complications such as reactive arthritis, Reiter's syndrome, and Guillain-Barré syndrome 2

Management of Recurrent Gastrointestinal Symptoms After Campylobacter Therapy – Focus on Clostridioides difficile Evaluation and Treatment

Initial Assessment – Rule Out C. difficile Infection

• Prompt stool testing for C. difficile toxin or toxin‑encoding genes is essential because prolonged exposure to azithromycin + metronidazole (used for 2 months) is a major risk factor for C. difficile infection. 6
• Antibiotic‑associated C. difficile infection recurs in roughly 20 % of patients, typically presenting with similar gastrointestinal symptoms within 8 weeks of the initial episode. [7][8]

Management of First Recurrence of C. difficile Infection

• The preferred regimen for a first recurrence is oral vancomycin 125 mg four times daily for 14 days, which is superior to metronidazole for recurrent disease. [6][7]8
• Fidaxomicin 200 mg twice daily for 10 days is an alternative that yields lower recurrence rates compared with vancomycin. [7][8]
• Metronidazole should be avoided for recurrent C. difficile because it has lower sustained response rates and carries a risk of cumulative neurotoxicity with prolonged use. [7][8]

Importance of Timely C. difficile Testing

• Delaying C. difficile testing is discouraged; recent antibiotic exposure is the primary risk factor and the resulting symptoms can closely mimic a Campylobacter relapse. [6][7]

Evaluation When C. difficile Tests Are Negative

• If both C. difficile testing and repeat Campylobacter cultures are negative, clinicians should investigate other etiologies such as post‑infectious irritable bowel syndrome, inflammatory bowel disease, or alternative enteric pathogens (e.g., Salmonella, Shigella, pathogenic E. coli). 9